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BACKGROUND. Cryptococcal meningitis (CM) causes an estimated 180,000 deaths
annually, predominantly in sub-Saharan Africa, where most patients receive fluconazole
(FLC) monotherapy. While relapse after FLC monotherapy with resistant strains is
frequently observed, the mechanisms and impact of emergence of FLC resistance in human
CM are poorly understood. Heteroresistance (HetR) — a resistant subpopulation within a
susceptible strain — is a recently described phenomenon in Cryptococcus neoformans (Cn)
and Cryptococcus gattii (Cg), the significance of which has not previously been studied in
humans.
METHODS. A cohort of 20 patients with HIV-associated CM in Tanzania was prospectively
observed during therapy with either FLC monotherapy or in combination with flucytosine
(5FC). Total and resistant subpopulations of Cryptococcus spp. were quantified directly from
patient cerebrospinal fluid (CSF). Stored isolates underwent whole genome sequencing
and phenotypic characterization.
RESULTS. Heteroresistance was detectable in Cryptococcus spp. in the CSF of all patients
at baseline (i.e., prior to initiation of therapy). During FLC monotherapy, the proportion of
resistant colonies in the CSF increased during the first 2 weeks of treatment. In contrast, no
resistant subpopulation was detectable in CSF by day 14 in those receiving a combination
of […]
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Introduction
Cryptococcal meningitis (CM) is a common and severe opportunis-
tic infection primarily affecting patients with advanced HIV/AIDS 
caused by the basidiomycete yeasts Cryptococcus neoformans (Cn) 
or less frequently Cryptococcus gattii (1). CM mortality is particu-
larly high in resource-limited settings where mortality can exceed 
50% even with antifungal treatment (2, 3). CM is invariably fatal 
without treatment (4). Recent estimates place the annual death toll 
from CM approaching 200,000 deaths per year, predominantly 
in sub-Saharan Africa (5). The gold standard of treatment for CM 
in HIV-infected patients is a 2-week induction regimen of ampho-
tericin B deoxycholate (AmB) combined with flucytosine (5FC), 
followed by a consolidation and then maintenance phase with oral 
fluconazole (FLC) (6). In many countries, however, and particularly 
those in sub-Saharan Africa, FLC is the only available antifungal; 
therefore, FLC monotherapy is used for induction, consolidation, 
and long-term maintenance regimes (7). Even with relatively high 
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Results
Following informed consent, 24 HIV-infected adult (age 18 or 
over) patients with a confirmed first episode of CM were prospec-
tively recruited in Dar es Salaam, Tanzania (Figure 1). The patients 
received either FLC monotherapy (800–1200 mg/day) in line with 
local and national treatment policies or in combination with 5FC 
(100 mg/kg/d in 4 divided doses) as part of the ACTA trial (Sup-
plemental Table 1; supplemental material available online with 
this article; https://doi.org/10.1172/JCI124516DS1). Serial clinical 
Cryptococcus isolates were obtained from 20 patients for pheno-
typic and genomic analyses (3 patients had culture-negative cryp-
tococcosis and one strain was unsuitable for study due to sample 
contamination with environmental mold). One strain (2201) was 
subsequently found to be C. gattii. Patient characteristics at base-
line are summarized in Supplemental Table 2. Baseline/pretreat-
ment MICs of 17 of the strains were susceptible using Clinical and 
Laboratory Standards Institute (CLSI) breakpoints extrapolated 
from Candida species (≤ 8 mg/l) (11), with the other 3 falling into 
the “susceptible, dose-dependent” category of 16–24 mg/l. By 
1-year follow-up of the study, 3 patients, all of whom had received 
FLC monotherapy, experienced clinical relapse. All-cause, 1-year 
mortality was 50% (Supplemental Table 2).
Detection of heteroresistance in all clinical strains prior to initia-
tion of fluconazole therapy. Ex vivo direct testing of patient CSF was 
performed by inoculating CSF within 1 hour of clinical sample col-
lection onto YPD agar supplemented with a range of FLC concen-
trations (8–64 mg/l). This identified a subpopulation of colonies 
able to grow on supra-MIC concentrations at baseline, prior to the 
patient receiving any FLC treatment. The growth on supra-MIC 
FLC concentrations was observed at a frequency ranging from 
0.01% to 25% of the total CFUs per milliliter of CSF.
Following a single passage on YPD agar, in vitro population 
analysis profiling (PAP) was used to measure the response to FLC 
of all stored baseline clinical isolates (strains ending in –01, Table 1) 
using a controlled starting inoculum of 1 × 106 cells. All strains 
were able to grow on agar containing FLC concentrations above 
MIC, as determined by Etest. At lower concentrations of FLC 
(8–32 mg/l MIC, depending on the strain), similar numbers of 
colonies appeared. These colonies were smaller and more trans-
lucent than colonies grown on drug-free agar. These colonies had 
the same MICs as colonies growing on drug-free agar, suggesting 
that they most likely represent tolerance, a transient ability to sur-
vive, at slower growth rates, on supra-MIC drug concentrations 
(28). At higher FLC concentrations, a small percentage of colonies 
were able to grow in the presence of FLC in a strain-dependent 
manner. When tested independently, these colonies had a signifi-
cantly elevated FLC MIC (≤ 4-fold) compared with the majority 
population, representing heteroresistance (Figure 2). PAP assay 
results were plotted as the log10 CFU/ml versus drug concentration 
and the AUC of the resistant subpopulation (i.e., the area under 
the curve of the PAP graph) was used as the parameter represent-
ing the heteroresistant subpopulation. The PAP curve can be split 
into 3 regions: (a) growth at concentrations below the MIC of the 
majority of the cells (susceptible); (b) visible but weak growth of 
the entire cell population on agar containing drug at concentra-
tions beyond its MIC (tolerant growth); and (c) growth of a sub-
population of colonies at supra-MIC drug concentrations, which 
doses of 1200 mg/day of FLC, CM treatment outcomes with FLC 
monotherapy as induction treatment are poor (2, 8).
The relationship between FLC resistance and CM treatment 
failure is not well understood. No clinical in vitro susceptibility 
breakpoints are available, because evidence for correlation between 
minimum inhibitory concentration (MIC) and outcome is sparse and 
conflicting (9, 10). Primary FLC resistance has not been considered 
as a major clinical problem because Cn generally displays low MICs 
to FLC in large epidemiological surveys (11). Nonetheless, clinical 
failure due to the recurrence of C. neoformans with high FLC MIC 
has been reported (12), and more recent data suggest FLC resistance 
(i.e., MIC > 8 mg/l) is as high as 10% in primary isolates and 24% in 
relapse isolates (13).
Heteroresistance to antifungal drugs is a recognized yet poorly 
understood subpopulation phenomenon observed in pathogenic 
fungi under drug pressure (14). As with bacteria such as Staphylo-
coccus aureus (15) and Mycobacterium tuberculosis (16), studies of 
heteroresistance in fungi have been hampered by a lack of consis-
tency in methodology and definitions (17, 18). Heteroresistance 
to FLC has been detected in clinical strains of Candida glabrata, 
although the mechanisms and clinical impact of this remain 
unknown (19). The phenomenon of heteroresistance to FLC in C. 
neoformans was first observed in vitro in 1999 (20, 21), and sim-
ilarly in C. gattii (22), but was only recently linked to emergence 
of FLC resistance via aneuploidy both in vitro and in animal stud-
ies (23). However, until now, no data on FLC heteroresistance in 
human cryptococcal infection have been reported.
In vitro studies of C. neoformans found FLC heteroresistance to 
be intrinsic, that is, present in all strains regardless of prior drug expo-
sure (24). Moreover, laboratory animal studies found that the size 
of the resistant subpopulation (the proportion of resistant cells as a 
percentage of the total) increases over time during FLC treatment 
(23). The predominant mechanism for this phenomenon appears to 
be aneuploidy, in particular transient duplication of chromosome 1 
(Chr1), in heteroresistant colonies of C. neoformans (25). Two genes 
on Chr1 are known to play an important role in cryptococcal resis-
tance to FLC: ERG11, which encodes the FLC target enzyme lanos-
terol-α-demethylase (26), and AFR1, an ABC-type efflux pump (27).
Here we examined the role of FLC heteroresistance in human 
cryptococcosis in a prospective observational study. This was 
done using cultures of serial samples of fresh ex vivo CSF on drug-
free and drug-containing media in a clinical cohort of 20 HIV- 
infected patients receiving FLC-based induction therapy for CM 
in Tanzania, East Africa. We found that FLC heteroresistance is an 
intrinsic feature of clinical Cn isolates in HIV-infected patients at 
CM diagnosis, with a resistant subpopulation ranging from 0.01 % 
to 25% of the total (%HetR). We demonstrated that disomy, par-
ticularly of Chr1, was common in baseline heteroresistant isolates 
and correlated with phenotypic measures of resistance in vitro, 
including MIC and efflux pump activity. Importantly, the size of 
the heteroresistant subpopulation increased (elevated %HetR) 
within 2 weeks in patients receiving FLU monotherapy. This lead 
to aneuploidy-mediated clinical relapse with elevated MICs in 2 
patients. Lastly, combination therapy with 5FC in addition to FLC 
was effective at suppressing amplification of the heteroresistant 
subpopulation in vivo, lending further support for oral combina-
tion therapies for African patients with CM.
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moderate, albeit statistically significant, relationship between 
the MIC and the level of heteroresistance (defined by the AUC 
of HetR) of a given clinical isolate (r2 0.35, P = 0.005), suggesting 
that MIC may not be a reliable predictor of heteroresistance.
Combination therapy with 5FC prevents amplification of flu-
conazole heteroresistance ex vivo. Prior to the start of the phase III 
Advancing Cryptococcal Treatment for Africa (ACTA) clinical 
trial (29) in Tanzania, patients received either FLC monotherapy 
at doses of either 800–1200 mg/day, standard practice per Tan-
zanian national treatment guidelines (30). After initiation of the 
ACTA trial, patients recruited to the trial and randomized to com-
bination therapy of FLC at 1200 mg/day with 5FC at 100 mg/kg/
day (4 divided doses of 25 mg/kg/d) as induction therapy were 
approached for inclusion in this substudy of heteroresistance. All 
when retested have a higher MIC than the parent strain (heterore-
sistant cells) (Figure 3).
Individual PAP curves for each strain show inter-strain vari-
ability, including variability in heteroresistance (measured by PAP 
assay) among strains with the same MIC level (measured by Etest) 
(Figure 3B). Using the AUC of this heteroresistant subpopulation 
as a proxy for heteroresistance level, we found that heteroresis-
tance is a continuous rather than a binary property. Furthermore, 
all but one of the clinical isolates analyzed in this study exhibited 
some degree of heteroresistance in vitro (Figure 3C). In vitro PAP 
assays reached results similar to the clinical assays of heteroresis-
tance (i.e., percentage of colonies growing on drug vs drug-free 
media) performed directly from patient CSF. Although baseline 
percentage of HetR colonies was generally low, there was only a 
Figure 1. Flowchart of patients recruited to the clinical observational study. Patients in cohort 1 received induction treatment as per local treatment 
policy, either 800 mg or 1200 mg per day FLC for the first 2 weeks. Patients in cohort 2 had already been randomized to receive FLC/5FC combined as part 
of the ACTA trial and were approached to consent to be observed as part of this substudy. Asterisk indicates fever plus one or more of headache, confusion 
or reduced level of consciousness.
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patients received 400 mg FLC monotherapy (or 800 mg until 
ART initiation) for an additional 8 weeks and then 200 mg daily 
thereafter, in accordance with national guidelines. The dynamics 
of the total CSF fungal burden in CFU/ml, as well as the size of the 
subpopulation of cells able to grow on FLC-containing media over 
the course of FLC therapy, is shown for each individual patient in 
Figure 4.
Early fungicidal activity (EFA), defined as the mean rate of 
decline in CSF log10 CFU/ml per day for each drug treatment group 
(Figure 5A) was consistent with prior cohorts (31). The combina-
tion of FLC/5FC had a significantly greater EFA compared with 
FLC monotherapy (mean + SD –0.11 ± 0.08, –0.13 ± 0.08 and –0.26 
± 0.02 log CFU/ml/d for FLC 800 mg, 1200 mg and combination 
therapy, respectively, P = 0.02 combination vs FLC, using the Stu-
dent’s t test). In addition to the faster rate of clearance, there was 
a notable difference in the amplification of heteroresistance in the 
combination therapy versus monotherapy groups. In all 5 patients 
receiving FLC/5FC combination therapy, the heteroresistant 
subpopulation was undetectable by day 14. In contrast, in 11 of 13 
patients (85%) receiving FLC monotherapy, within the first 7 days 
of treatment, the heteroresistance level increased: the proportion 
of the subpopulation with an elevated MIC to FLC increased as 
a proportion of the total CSF fungal burden (the 2 other patients 
died before day 7). We next calculated the rate of change in %HetR 
per day as a summary statistic for FLC monotherapy versus combi-
nation treatment. In patients receiving FLC monotherapy, the rate 
of change of HetR was significantly greater than in those receiving 
the FLC/5FC combination (mean ± SD 4.55 ± 6.77 per day versus 
–0.70 ± 1.13 per day, respectively, P = 0.019). Amplification of HetR 
was higher in patients receiving the lower dose of FLC (800 mg/d) 
although this difference did not reach statistical significance (5.80 
± 7.78 per day versus 1.76 ± 2.62 per day, P = 0.19) (Figure 5B). Rate 
of change of HetR was not associated with baseline fungal burden 
(CFU/ml of CSF) or with the baseline HetR level (AUC of HetR in 
vitro) of the infecting strain.
In this small cohort, baseline HetR (as measured by AUC in 
the PAP assay) was not significantly associated with clinical mark-
ers of CM severity at presentation, including baseline fungal bur-
den (P = 0.9), reduced Glasgow Coma Score (GCS) (P = 0.33), and 
raised intracranial pressure (P = 0.37), nor with 2-week, 10-week, 
or 1-year mortality (P values 0.5, 0.7, and 0.4, respectively).
Combination therapy can prevent amplification of fluconazole 
heteroresistance in vitro. We assessed whether this amplification 
or suppression of HetR could be replicated in vitro using the cor-
responding clinical strains. Two baseline (pretreatment) clinical 
strains were chosen: 1501, (from patient 15), in which HetR had 
amplified during FLC monotherapy, and 1901 (from patient 19), 
who had been treated successfully using combination FLC/5FC.
The 2 baseline (pretreatment) clinical isolates were main-
tained in liquid YPD plus 16 mg/l FLC, and YPD plus 16 mg/l FLC 
and 16 mg/l 5FC (also at 16 mg/l), conditions chosen to reflect 
plasma drug levels in the patients undergoing FLC monotherapy 
and FLC/5FC combination therapy, respectively (32, 33). The 
cultures were sampled daily for 5 consecutive days and plated to 
YPD alone and to YPD agar plus FLC (8, 16, 32, and 64 mg/l) and 
the total CFU and %HetR were calculated. For strain 15, %HetR 
increased during in vitro growth in YPD plus FLC, in a manner 
Table 1. Whole-genome–sequenced strains
Patient Strain name Day of treatment
1 0101 1
0101R 1
0120 20
0190 90
2 0201 1
0201R 1
0290 90
02365 365
3 0301 1
0301R 1
6 0601 1
0601R 1
7 0701 1
0701R 1
0715 15
8 0801 1
0801R 1
0815 15
9 0901 1
0901R 1
0914 14
10 1001 1
1001R 1
1011 11
11 1101 1
1101R 1
1107 7
13 1301 1
1301R 1
14 1401 1
1401R 1
1405 5
15 1501 1
1501R 1
1513 13
16 1601 1
1601R 1
17 1701 1
1701R 1
1717 17
18 1801 1
1801R 1
19 1901 1
1914 14
21 2101 1
2101R 1
22 2201 1
2201R 1
23 2301 1
2301R 1
24 2401 1
2401R 1
The following naming scheme was used: patient number from which the 
isolate was obtained, followed by the day since initiation of treatment with 
fluconazole. The addition of R as a suffix indicates heteroresistant colonies, 
that is, those selected on FLC-containing media (highlighted in bold). For 
example, strain 0101R is from patient 01, on day 1 of treatment, and selected 
on FLC-containing media.
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average of 59 times coverage (± 37 SD). High confidence variants 
were identified (see Methods) for further comparative and evolu-
tionary studies. Full alignment, coverage, and variant calling sta-
tistics are provided in Supplemental Table 3.
Phylogenetic analysis revealed 19 C. neoformans isolates of 
the VNI genotype, and 1 C. gattii isolate of the VG1 genotype (iso-
lates from patient 22). On average, 747 SNPs separated isolates 
within the same subclade, and isolates in this study accumulated 
on average 74 SNPs/day, ranging from 1 SNP/day/patient to 842 
SNPs/day/patient. This wide range in SNP accumulation is likely 
to represent coinfection by genetically differentiated genotypes 
occurring in the environment. We found no nonsense mutations 
in either the MSH2 gene or SFG29 gene, which have been impli-
cated as causes of hypermutators, that is, strains of Cryptococcus 
that accumulate large numbers of SNPs per day (35–37).
Aneuploidy of Chr1 was observed in a baseline unselected col-
ony in 1 of the 20 isolates (strain 1101). Notably, this strain also 
had an elevated pretreatment FLC MIC (24 mg/l), and aneuploidy 
was present in the HetR colonies (selected by growth on FLC) in 
12 of the 20 isolates (Figure 7). This was most commonly disomy 
of Chr1 (9 of 12 HetR baseline isolates), with partial or whole copy 
number variations of chromosomes 2, 6, 10, 11, 12, and 14 also 
observed in the HetR colonies. The ploidy of parental and HetR 
colonies of all 20 clinical strains are summarized in Figure 8.
In order to explore potential mechanisms of heteroresistance 
in the nonaneuploid strains, nonsynonymous SNPs unique to the 
HetR colony as compared with the unselected colony for all strains 
were determined from the sequence data. Nonsynonymous SNPs 
occurring in several coding genes were observed in more than one 
strain. Table 2 ranks these SNPs based on how frequently they 
were observed, and whether they were noted in aneuploid and 
nonaneuploid strains. Interestingly, nonsynonymous mutations 
of CNAG_03040, a transkelotase gene, were observed in 4 of the 
8 resistant colonies of nonaneuploid strains, but not in any of the 
similar to that in the patient upon treatment (compare Figure 6A 
with Figure 6B), whereas when the same strain was grown in YPD 
plus FLC and 5FC medium, complete suppression of growth upon 
subculture on FLC agar was seen as early as 24 hours (Figure 6C). 
Similar results were obtained with strain 19. Exposure to FLC alone 
resulted in amplification of the HetR level in vitro (Figure 6E), and 
growth in FLC plus 5FC suppressed amplification of the HetR 
subpopulation on FLC similarly to that observed in vivo (compare 
Figure 6D with Figure 6F). However, in contrast to the clinical 
trajectories observed in the corresponding patient, in whom the 
subpopulation remained suppressed by combination therapy over 
time, during in vitro passage of strain 1901 with a combination of 
FLC and 5FC, HetR colonies reappeared 24 hours after initial sup-
pression. Interestingly, at this point in the in vitro growth, strain 
1901 progeny grown in vitro had acquired phenotypic resistance 
to 5FC (MIC by Etest of >32 mg/l), which effectively disabled the 
additional effect of the 5FC.
HetR is associated with aneuploidy, particularly chromosome 1 
disomy. Cryptococcal DNA was extracted and sequenced from 
all 20 baseline isolates grown on YPD agar (i.e., from unselected 
colonies, strains 0101–2401) and from corresponding colonies 
from each of the 20 baseline strains grown on YPD with FLC 
(from 8–64 mg/l) added (HetR subpopulation, selected, strains 
0101R–2401R). Additionally, where available, serial isolates (at 
the end of induction therapy and at clinical relapse if applicable) 
had DNA extracted for whole-genome sequencing (WGS). Strains 
sequenced are summarized in Table 1. DNA was extracted from 
single colonies. Sequence data are available at the European Nucle-
otide Archive (ENA, https://www.ebi.ac.uk/ena, accession num-
ber PRJEB28390). Sequences were analyzed for ploidy (based on 
genome-wide normalized coverage), and the presence of unique 
nonsynonymous SNPs between the parent and HetR isolates.
We recovered an average of 10.9 million reads from each iso-
late, with an average of 96.7% reads mapping to H99 (34), and an 
Figure 2. Phenotypes of tolerance and heteroresistance. Cn (106) cells from the H99 reference strain showing colonies growing at the same quantity but 
smaller and more translucent at 16 mg/l. These colonies have the same MIC as the parent strain (1 mg/l) and are thought to represent tolerance. When 
plated on 32 mg/l FLC, a small percentage of opaque, medium-sized colonies appear, and have MIC of 256 mg/l, far higher than the parent strain. This 
represents true heteroresistance.
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Figure 3. Heteroresistance 
is a continuous variable 
in clinical C. neoformans 
isolates. Population analysis 
profile (PAP) curves: CFUs 
per milliliter plotted against 
increasing concentrations of 
FLC. Dark green represents 
the susceptible population. 
Middle shade of green is the 
growth beyond the MIC of the 
strain, which grows poorly yet 
in a quantity similar to that 
grown on plain agar, and has 
the same MIC as the strain as 
a whole. The lightest shade 
of green is the subpopulation 
of colonies, which grows as a 
small percentage of the total 
but has an elevated MIC as 
compared with the dominant 
population, heteroresistance 
(HetR). (A–T) PAP curves for 
each of the 20 clinical isolates 
demonstrating heterogeneity 
in the AUC of HetR even for 
strains with similar MICs. 
Data points with error bars 
represent mean of quadrupli-
cates ± SEM. (U) Distribution 
of heteroresistance (as defined 
by AUC of the subpopulation 
growing beyond the MIC, HetR) 
of the clinical isolates in the 
study, demonstrating a contin-
uous distribution, rather than 
heteroresistance being a binary 
property of a strain.
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strains with chromosomal disomy. The significance of this is not 
immediately clear, but provides a candidate gene for further study.
Clinical relapse and HetR is associated with Chr1 disomy. Relapse 
of CM is a recognized risk of FLC monotherapy (12). In this study, 
3 of the 15 patients on FLC monotherapy relapsed with symptom-
atic CM (headache, fever, altered mental status); none of the com-
bination therapy patients relapsed. In all relapse cases, lumbar 
puncture was performed and C. neoformans was cultured from the 
CSF onto YPD (nonselective) media and sequenced. In 2 of the 3 
patients, the relapse isolate was aneuploid and was associated with 
an increase in MIC compared with the original baseline parental 
strain, as well as an increase in %HetR at each relapse time point 
(Figure 9, A and B). In the third patient, in whom no changes in 
MIC or aneuploidy were observed, the relapse was considered to 
be due to the patient’s self-reported nonadherence to FLC.
To investigate whether the aneuploid chromosomes in these 
relapse isolates were stable, we cultured the relapse isolates for 
patients 1 and 2 in liquid YPD (without drug), and sampled them 
daily to measure MIC to FLC until reversion to baseline MIC was 
seen. Both relapse strains reverted to the baseline MIC after 10 
Figure 4. FLC monotherapy causes an increase in the resistant subpopulation in patient CSF, which can be prevented by the addition of 5FC. Fungal 
burden dynamics for each patient according to treatment received. The black line is the total population in CSF (log10 CFU/ml in CSF) whereas the red line 
is the subpopulation that grew on FLC-containing agar. (A–O) Patients receiving monotherapy, amplification of the resistant subpopulation is observed. 
(P–T) In the combination group, the subpopulation is undetectable by day 14 in all cases.
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Heteroresistance is associated with increased efflux pump activ-
ity. The rhodamine 6G (R6G) assay measures the efflux activity 
of ABC-like transporters, which is ATP-dependent and is dramat-
ically reduced in the absence of glucose (38). Glucose-induced 
efflux was measured in all 20 baseline strains and normalized 
to H99 efflux levels. Efflux of R6G correlated positively with the 
HetR AUC, with a lower, nonsignificant correlation with %HetR 
in patient CSF (Pearson r = 0.49, P < 0.001 and r = 0.15, P = 0.09, 
respectively, Figure 10A). In addition, there was a significant asso-
ciation between HetR isolates with Chr1 disomy and efflux activity 
(P = 0.004, Kruskal-Wallis test).
We next used RT-PCR to assay the expression levels of 2 rele-
vant genes on Chr1: AFR1, which encodes a drug efflux pump, and 
ERG11, encoding the FLC target enzyme. A high efflux clinical strain 
with aneuploid heteroresistance (0101) and low efflux clinical strain 
with euploid heteroresistance (1601) were selected for compari-
son to the H99 reference strain. The genes AFR1 and EGR11 both 
exhibited significantly greater expression relative to the GPD gene 
(located on chromosome 7) in the Chr1 disomic HetR isolate 0101 
as compared with strain 1601. The difference in expression was 
approximately 2-fold, presumably a consequence of disomy of Chr1 
in strain 0101 as compared with the aneuploid 1601 (Figure 10B).
and 12 passages, respectively. Importantly, reversion to the base-
line MIC was accompanied by loss of the relevant aneuploidies 
(“P” in Figure 9, A and B), consistent with the hypothesis that the 
aneuploidies are responsible for the HetR phenotype in these iso-
lates and that they incur a fitness cost in the absence of drug selec-
tion leading to a reversal of the HetR phenotype.
Of the patients who had CSF samples taken in the second 
week of induction treatment, sequences were obtained from col-
onies unselected by FLC agar, and examined for ploidy. Although 
amplification of HetR in terms of percentage of colonies grow-
ing on FLC-containing agar increased within this early period of 
treatment, we did not detect aneuploidy in unselected colonies 
at this early stage (11–17 days), unlike in the later relapse isolates 
described above. The only exception was strain 17, where disomy 
of Chr2 appeared at this early stage. The day 17 isolate had Chr13 
disomy in the day 0 strain, yet Chr1 disomy was not detected at 
day 17 in the unselected culture, despite Chr1 disomy being pres-
ent in the corresponding HetR colony at baseline (Figure 8). The 
diversity of genome sequence in this particular strain between 
parental and HetR colonies suggested a mixed population of C. 
neoformans, which may explain the diversity detected in different 
colony isolates.
Figure 5. A combination of FLC and 5FC clears Cryptococcus faster from CSF, and also prevents the emergence of a FLC-resistant subpopulation. (A) EFA 
of monotherapy (n = 15) and combination treatment (n = 5), showing a faster rate of clearance in the combination arm (P = 0.02). (B) Mean rate of change 
of %HetR per day by treatment group was significantly different between the groups, with combination arm suppressing rather than amplifying the sub-
population (P = 0.019). Individual data points with SEM are displayed. Two-tailed Student’s t test, with P < 0.05 considered significant.
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are unlikely to be suitable for routine clinical surveys. Novel tech-
niques such as diskImageR, an image analysis pipeline for disk 
diffusion assays (39), can be useful for detecting tolerance and 
the consequent likelihood of recurrence of infection in C. albicans 
(28). However, C. albicans tolerance involves subpopulation sizes 
of greater than 10%. The low frequency of HetR in baseline pop-
ulations may require the development of alternative approaches 
to measure HetR. With current clinical tools, heteroresistance is 
likely to continue to go undetected and to contribute to the failure 
of FLC monotherapy in treating human CM.
The combination of FLC with 5FC provides a faster rate of 
CSF fungal clearance as compared with FLC monotherapy (31). 
The ACTA trial, of which this is a substudy, recently reported the 
noninferiority of FLC plus 5FC combination therapy in terms of 
mortality outcomes compared with 2 weeks of AmB-based ther-
apy, the long-standing gold standard, for induction treatment 
of HIV-related CM (40). Important advantages of the FLC plus 
5FC combination are as follows: (a) it can be administered oral-
ly, (b) it is well tolerated compared with the relatively toxic AmB 
(29), and (c) it has the potential for generic manufacture, mak-
ing it affordable for low and middle income countries (41). As a 
direct result of the ACTA trial, FLC plus 5FC as a combination is 
recommended in new WHO guidelines for induction treatment 
of CM in areas where AmB cannot be given (42). The data pre-
sented in our study provide evidence of a further benefit from 
combination therapy: it suppresses the amplification of HetR, 
an underestimated precursor of treatment failure, due to the 
appearance of resistance during the maintenance and consoli-
Discussion
In this clinical microbiological study, we studied an African clin-
ical cohort with intensive serial microbiological and genomic 
sampling of ex vivo patient CSF. We found that heteroresistance 
to FLC is intrinsic to clinical strains of Cn causing HIV-associated 
CM. In addition, CM induction treatment with FLU monotherapy 
can increase the size of HetR cryptococcal subpopulations that 
accumulate aneuploidies, a property associated with loss of micro-
biologic control and eventual clinical relapse with FLC resistance. 
Furthermore, this phenomenon appears to be suppressed by the 
use of FLC plus 5FC combination therapy in the clinical setting 
and in early time points of in vitro growth as well.
These results have clinical and microbiologic implications. In 
agreement with prior in vitro studies (24), most strains were het-
eroresistant at baseline, prior to the administration of any FLC 
treatment, in a strain-dependent manner. This implies that stand-
ing variation in the population of the infecting strain includes 
cells with aneuploidies that can provide a growth advantage in 
the presence of FLC. Routine diagnostic testing by Etest or broth 
microdilution does not measure HetR; it generally involves a sub-
population size that is too small to be detected with these assays. 
Thus, HetR is a subtlety missing in epidemiological MIC surveys 
that report low rates of primary resistance. Transience is a key 
feature of heteroresistance, distinguishing it from stable, genetic 
mutation-derived resistance. The transient nature of FLC resis-
tance due to aneuploidy also confounds its detection because it 
is rapidly lost upon removal from drug pressure. PAP assays, the 
gold standard measure of HetR, are labor- and time-intensive and 
Figure 6. Amplification or suppression of heteroresistance in the clinical setting can be reproduced in vitro. In vitro experiments performed by 
inoculation of clinical strain into YPD with the addition of FLC with or without 5FC. Black line indicates total CFUs per milliliter at each sample time 
point. Red line indicates the heteroresistant subpopulation derived by CFUs per milliliter growing on YPD plus fluconazole. Data points with error bars 
represent the mean ± SEM of quadruplicated experiments. (A) Strain 1501 clinical data showing increased proportion of resistance. (B) Strain 1501 
grown in YPD with the addition of 16 mg/l FLC. (C) Strain 1501 grown in YPD with the addition of 16 mg/l FLC and 16 mg/l 5FC. (D) Strain 1901 clinical 
data. (E) Strain 1901 grown in YPD with the addition of 16 mg/l FLU. (F) Strain 1901 grown in YPD with the addition of 16 mg/l FLC and 16 mg/l 5FC. This 
strain had acquired resistance to 5FC.
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storage, shipment, and then receipt of samples. Analysis of isolates 
with as few passages as possible minimizes the pitfalls of repeated 
storage and passage that can lead to a loss of transient genomic 
changes such as aneuploidy, and have hampered prior studies of 
genomic evolution in serial clinical isolates of C. neoformans and C. 
gattii (46). Using this translational approach, we captured aneuploidy 
(most commonly disomy of Chr1) as a dominant, but not exclusive, 
feature of heteroresistant cells in the clinical setting. Relapse isolates 
of patients revealed stepwise duplication of whole chromosomes 
with an associated increase in MIC accompanied by clinical and 
microbiologic failure, in a manner similar to that observed in mouse 
studies (25). In addition, in one patient, an infecting strain with a 
high MIC to FLC was found to be disomic for Chr1 without any prior 
exposure to FLC. To our knowledge, this is the first such report of 
Chr1 disomy in a wild-type, baseline (untreated) infecting strain of 
Cn from a clinical case of CM.
We propose 2 mechanisms for the increase in the proportion 
of HetR cells within a population. First, selection during growth in 
FLC is expected to inhibit the growth of susceptible cells, allowing 
the preexisting HetR subpopulation to proliferate. Second, FLC has 
the ability to induce the appearance of loss of heterozygosity, poly-
ploidy, and aneuploidy in both C. albicans (47) and C. neoformans 
(48). In C. albicans, FLC alters cell-cycle progression, resulting in 
the formation of trimeras, 3 connected cells whose aberrant nuclear 
replication ultimately results in unstable tetraploids that give rise 
to aneuploids (49). Similar effects of FLC exposure have been 
observed in C. neoformans, although no evidence was presented to 
show that aneuploid cells originate from multinucleated or poly-
ploid cells (48). FLC induces the formation of multinucleated cells 
by causing uncoupling between nuclear division and cytokinesis. 
Cn has also been shown to form titan cells—large, polyploid cells 
that appear to have a significant impact on cryptococcal pathogen-
esis by evading phagocytosis by immune escape and host dissem-
ination (50, 51). On exposure to FLC, titan cells appear to produce 
aneuploid daughter cells that are resistant to FLC (51). Cn titaniza-
tion may play a role in generating the aneuploid subpopulations 
dation phases of CM treatment, when FLC monotherapy is used 
as induction. Furthermore, persistence, tolerance, and heterore-
sistance are adaptive features across a wide range of microbial 
species, including eukaryotic and prokaryotic human pathogens 
(19, 43–45). Accordingly, we suggest that the principle of HetR 
suppression using relevant combination therapy strategies can 
be extrapolated to myriad other infectious diseases, including 
staphylococcal and mycobacterial infections.
The heteroresistance assay used here was performed ex vivo, 
that is, near bedside with minimal delay between sampling CSF 
from the patient and plating for cultures, and thus is a close repre-
sentation of the phenotypic changes occurring within the human 
central nervous system during the course of cryptococcal infection. 
Genomic analysis of the isolates was performed after minimal pas-
saging, although freeze/thaw cycles were unavoidably required at 
Figure 7. Whole-genome sequencing revealed high rates of aneuploidy 
in heteroresistant colonies. Summary of ploidy in resistant colonies com-
pared with parental strains based on genome sequences and frequency of 
disomy per chromosome observed in the aneuploid clinical study isolates; 
chromosome 1 disomy was predominant.
Table 2. Recurrent nonsynonymous SNPs in heteroresistant but euploid strains
Gene Name Frequency  
(out of 20)
Seen in aneuploid  
hetR colonies
Seen in euploid  
hetR colonies
Seen in posttreatment, 
unselected colonies
CNAG_05395 Rab guanyl-nucleotide  
exchange factor
8 4 4 Yes
CNAG 01891 Rad57 6 2 4 Yes
CNAG_07846 Ran-binding protein 3 6 3 3 Yes
CNAG_06058 Protein DGCR14 4 2 2 Yes
CNAG_03040  Transketolase 4 0 4 Yes
CNAG_00426 UBA/TS-N domain–containing protein 4 1 3 Yes
CNAG_05059 Pyruvate dehydrogenase E1 component 
subunit beta
4 1 3 No
CNAG_05330 MFS transporter, SP family, general alpha 
glucoside: H+ symporter
3 2 1 No
CNAG_00867 Myo-inositol transporter 2 0 2 No
CNAG_04278  DNA ligase 1 2 2 0 Yes
Most commonly identified nonsynonymous SNPs unique to colonies growing on fluconazole agar as compared with those growing on plain YPD, using H99 
as the reference genome. 
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strains are likely to have been aneuploid, although ploidy was 
not determined in that particular study (24). Chromosomal copy 
number variation, in particular whole chromosome duplication 
(disomy in a haploid like Cn), is a potentially rapid mechanism to 
generate genomic diversity. Chromosome copy number increases 
may provide a selective advantage under many different stressors, 
including environmental challenges, due to the extra expression of 
hundreds to thousands of genes present on each chromosome (56).
The reversion to euploidy in the absence of drug stress sug-
gests that aneuploids bear a fitness cost that is no longer worth 
bearing in the absence of fluconazole selection. A previous study 
found the heteroresistant colony derived from the H99 strain to be 
less virulent in mice than in the parental strain, and to grow more 
slowly in vitro (25). However, aneuploid strains appear, in this 
study, to retain sufficient virulence to cause clinical disease, either 
at baseline or relapse, and Sionov et al. in 2009 found highly HetR 
strains to be more virulent in mice than low HetR strains (24). This 
may be, in part, due to the profound immune suppression of the 
seen in Cn. Their role in promoting increased levels of heteroresis-
tance has yet to be determined and is an avenue of future study.
Dysfunction in apoptosis regulation may also allow aneuploid 
cells to persist in the population. In the absence of Aif1, a protein 
that induces apoptosis-like cell death in C. neoformans, populations 
have a higher frequency of Chr1 disomy and FLC resistance (52). 
Nonetheless, no mutations of Aif1, unique to the HetR rather than 
unselected colonies, were found in the clinical isolates studied here.
The high incidence of aneuploidy and heteroresistance, even 
prior to exposure to FLC, suggests that aneuploidy is already pres-
ent in environmental Cryptococcus strains, some of which will pro-
ceed to infect humans. Genome plasticity, and in particular aneu-
ploidy, is increasingly recognized as an adaptive stress response in 
both bacteria and pathogenic eukaryotes (43). Indeed, aneuploidy 
has been noted in environmental strains of Saccharomyces cervisiae  
(53) as well as C. neoformans (54), although more rarely than in 
clinical isolates (55). Environmental strains of C. neoformans have 
also been found to be heteroresistant, suggesting many of these 
Figure 8. Aneuploidy is common in FLC-resistant colonies, in particular disomy of chromosome 1. Summary of ploidy data. (A) Chromosome maps of all 
20 strains when a colony growing on plain YPD was sequenced. Only one strain has aneuploidy unselected colonies. (B) Corresponding chromosome maps 
of sequences from colonies selected on FLC-containing agar. Aneuploidy is common, in particular chromosome 1.
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patients’ CSF at baseline. This is likely because PAP assays use a 
controlled inoculum and standardized methodology, in contrast 
to the bedside CSF analysis, which is subject to highly variable 
fungal burdens and host immune responses. The sequencing 
analyses are also limited by being based on sequences of single 
colonies, which does not account for the possibility of colony- 
to-colony variation or, indeed, the possibility of cell-to-cell varia-
tion. The advent of single-cell sequencing and the reducing cost 
of WGS may make sequencing of multiple colonies or single cells 
feasible in future studies.
In summary, this clinical study of the evolution and mecha-
nisms of resistance to FLC in human CM is the first, to our knowl-
edge, to detect the presence and emergence of FLC heteroresis-
tance in human CM and to report the successful suppression of 
heteroresistance with 5FC plus FLC combination therapy. We 
believe this is the first prospective clinical study to examine the 
role of aneuploidy in CM patients, and to confirm and build upon 
previous work in a mouse model of Cryptococcus infection showing 
emergence of disomy during FLC treatment (23). In addition, this 
study suggests that the accumulation of aneuploidies, especially 
Chr1 disomy, is one of the mechanistic bases for clinical treatment 
failure and drug resistance. These findings provide another nail in 
patients in our cohort, which can allow for relatively less fit strains 
to establish clinical disease.
Clearly, aneuploidy is not the only pathway to heteroresistance 
in C. neoformans, as in HetR clinical strains that were not aneuploid, 
the proportion of HetR colonies also increased during the course of 
therapy in the patient. The mechanism of heteroresistance in these 
nonaneuploid strains remains to be determined. Here we identi-
fied a number of candidate genes, based on recurrently observed 
SNPs in nonaneuploid yet heteroresistant and therefore transiently 
drug-resistant strains, that warrant further investigation (Table 2). 
Interestingly, nonsynonymous SNPs in RAD57, a protein involved 
in DNA repair, were seen in 6 of the strains, raising the possibility 
that this may have a role in the emergence of aneuploidy, although 
this will require further investigation.
This study is limited by small numbers and is therefore not 
powered to detect the significance of heteroresistance in clinical 
outcomes such as mortality. In addition, the method of detecting 
heteroresistance by culturing on FLC-containing agar raises the 
possibility of ex vivo induction of the phenomenon. However, it is 
unlikely induction would occur in the time course of a single pas-
sage. Efflux pump activity correlated with the HetR AUC derived 
from the PAP assays, though not with the %HetR colonies in the 
Figure 9. Clinical relapse of cryptococcal meningitis with high MIC to FLC is associated with transient chromosomal duplication. (A) Ploidy of sequenced 
(unselected) colonies from study patient 1 at baseline (pretreatment) and during FLU monotherapy (day 20 and at clinical relapse on day 90). The day 90 
isolate was resistant (FLU MIC >256 μg/ml by Etest), with a corresponding increase in %HetR (proportion of colonies growing on fluconazole-containing 
agar as compared with total growing on drug-free YPD) and disomy of chromosome 1. The relapse isolate was then passaged serially for 12 days (labeled P) 
and then sequenced, revealing loss of disomy and reversion to a sensitive phenotype. (B) Another study patient (patient 2) who experienced 2 relapses at 
days 90 and 365, with a stepwise increase in disomies (1, 4, and 12) noted on isolates obtained from the patient CSF at each time point with corresponding 
increases in %HetR and MIC. As with the patient in A, on serial passage in plain YPD the isolate reverted to a euploid, low MIC phenotype.
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were processed within 1 hour of collection from the patient. CSF was 
vortexed and plated onto YPD in serial 10-fold dilution for counting 
colony-forming units. CSF was also plated onto plain YPD agar and 
YPD with the addition of 8, 16, 32, 64, and 128 mg/l FLC. Plates were 
incubated at 30°C for 7 days and colonies were counted manually. CFUs 
per milliliter were calculated after adjustment for the dilution counted.
MICs. MICs to FLC were measured using the Etest method accord-
ing to the manufacturer’s instructions (BioMérieux). Testing was done 
on-site in Dar es Salaam, Tanzania. A 0.5 McFarland standard suspen-
sion of the strain was prepared in 0.45% saline and spread in 3 planes 
using a cotton swab onto RPMI agar (Sigma-Aldrich). Etest strips (Bio-
merieux) were applied to the plate and incubated for 48 hours. MIC 
was determined as the point where the ellipse met the strip. MICs were 
performed in triplicate. The median was calculated and rounded up to 
the nearest concentration.
Population analysis profile. PAP assay was performed using a pre-
viously described method (17). Briefly, 106 cells of C. neoformans were 
plated on plain YPD agar and YPD with 8, 16, 32, 64, and 128 mg/l FLC 
added to the agar. Serial 10-fold dilutions were plated in order to count 
colonies, and plates were incubated at 30°C for 5 days.
In vitro drug evolution. A 1 × 106 suspension of cells in 10 ml YPD 
liquid (plus 1% penicillin/streptomycin) was prepared in 15-ml tubes 
for each experiment. FLC and 5FC were added to the tubes to a final 
concentration of 16 mg/l of both drugs within the tube. Tubes were 
incubated at 30°C and shaken at 225 rpm. Every 24 hours the tubes 
were removed and vortexed, and 1 ml of fluid was sampled. The sam-
ple was plated on YPD and YPD with FLC, and serially diluted 10-fold 
up to a 1 in 1000 dilution to facilitate colony counting. Plates were 
incubated at 30°C for 5 days and colonies manually counted, with 
CFUs per milliliter calculated after adjustment for the dilution factor 
of the plates counted.
In vitro evolution of heteroresistance study. From 1 colony of the 
study strain, a solution of 1 × 107 cells in PBS was prepared. After vor-
texing, 1 ml of this suspension was added into 9 ml filtered YPD broth 
in 4 × 15 ml falcon tubes. Ampicillin was added to prevent bacterial 
contamination. Into each tube was added (a) nothing (control), (b) flu-
conazole to a final concentration of 16 mg/l, (c) flucytosine to a final 
concentration of 16 mg/l, and (d) both FLC and 5FC at 16 mg/l each. 
Each tube was vortexed and incubated at 30°C with shaking at 225 
the coffin of FLC monotherapy, which is an inadequate induction 
regimen for patients with HIV-related CM.
Methods
Observational clinical study. From May 2015 to October 2016, nonpreg-
nant patients older than age 18 with a laboratory-confirmed first epi-
sode of HIV-associated CM were recruited from Muhimbili, Amana, 
and Mwananyamala hospitals in Dar es Salaam, Tanzania. Prior to the 
start of the ACTA trial, patients received FLC treatment, as remains 
the local standard practice. After initiation of the ACTA trial, patients 
within the trial who were allocated to combination therapy with FLC at 
1200 mg/day plus 5FC at 100 mg/kg/day (4 divided doses of 25 mg/
kg/d) as induction therapy were approached for inclusion in the study. 
Lumbar punctures were performed on days 1, 7, and 14, or more fre-
quently if clinically indicated. Patients were followed for 1 year.
Ethics statement and study approvals. The clinical study in Tanza-
nia was performed with approval from the ethics committees of both 
the London School of Hygiene and Tropical Medicine (ethics refer-
ence 9176) and the National Institute of Medical Research in Tanzania 
(ethics reference NIMR/HQ/R.8a/Vol. IX/1905). Written informed 
consent was taken from all study patients or next of kin if they were 
unable to consent due to altered mental status.
Strains used. All clinical isolates were obtained prospectively from 
the clinical study performed for the purposes of this study and collected 
by the authors. Strains are labeled by patient number followed by the day 
of treatment; for example, strain 0101 is from patient number 1, day 1 of 
study (pretreatment). The C. neoformans var grubii H99 strain was used 
as a reference control strain in all in vitro experiments.
Culture media. Strains were cultured on yeast extract peptone dex-
trose (YPD) agar. Drug-containing plates were made by the addition 
of a stock solution of 50 mg/ml FLC powder (Alfa-Aesar) in DMSO, 
to final concentrations of 8, 16, 32, and 64 mg/l. Drug was added to 
the agar after autoclaving, then cooled to approximately 50°C before 
pouring. Penicillin/streptomycin (Hyclone, GE Life Sciences) was 
added to prevent bacterial contamination.
Quantitative cryptococcal cultures. These were performed using 
a modification of previously published protocol (57). Briefly, lumbar 
punctures were performed on patients on days 1, 7, and 14 of treat-
ment if possible, or more frequently if clinically indicated. Samples 
Figure 10. Heteroresistance is associated with increased efflux, and expression of ERG11 and AFR1 genes. (A) Heteroresistance is associate with 
increased efflux activity efflux activity (mean of triplicate experiments, normalized to H99, reference strain) correlates with heteroresistance as defined by 
AUC from PAP experiments (Pearson correlation coefficient r = 0.49, P < 0.001). (B) High efflux, disomic strain 1 compared with low efflux, euploid strain 
16 shows approximately 2-fold increased expression of ERG11 (fluconazole target) and AFR1 (efflux pump). Data points represent results of experiments in 
triplicate with error bars displaying mean ± SEM.
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Quality control was performed using the Tapestation High Sensitiv-
ity D1000 ScreenTape (Agilent). DNA libraries were prepared using 
the NEBNext DNA library preparation kit (New England Biolabs). 
Sequencing was performed on the Illumina NextSeq platform with 
single-end reads of 150 bp length, at both the Weizmann Institute of 
Science, Rehovot, Israel, and the Centre for Genome Enabled Biology 
and Medicine at the University of Aberdeen, United Kingdom.
Raw Illumina reads were quality checked using FastQC v0.11.4 
(Babraham Institute). All reads contained adaptor sequences which 
were trimmed using Trim Galore! v0.4.1 (Babraham Institute). All 
trimmed reads were aligned to the C. neoformans reference genome 
H99 (34) using the Burrows-Wheeler Aligner (BWA) mem v0.75a 
algorithm, and converted to sorted BAM format using SAMtools v1.2. 
Picard v1.72 (http://broadinstitute.github.io/picard) and Genome 
Analysis Toolkit (GATK) v3.4-46 were used to mark duplicates and 
preprocess the alignments prior to variant calling. Base recalibration 
was performed using GATK. Variants were called using GATK Haplo-
typeCaller and filtered to obtain a high-confidence variant that passed 
the parameters “DP < 5 || MQ < 40.0 || QD < 2.0 || FS > 60.0.” All SNPs 
were annotated using VCFannotator (Broad Institute).
Phylogenies of whole-genome SNP data were generated by RAxML 
v8.2.4 using the rapid bootstrap algorithm over 500 replicates for the 
best-scoring maximum likelihood tree. Phylogenies were visualized and 
annotated in FigTree v1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/).
Depth of coverage was calculated using GATK from the whole- 
genome alignment. Ploidy analysis and chromosome coverage map 
figures were generated using the YMAP analysis pipeline (58).
Statistics. Graphs and AUC analyses were generated with Prism (v5, 
Graphpad Software Inc.). All other statistical analyses were performed 
using STATA version 13.1. A 2-tailed Student’s t test was used to com-
pare mean changes in resistant subpopulations and total fungal between 
treatment groups. A P value of less than 0.05 was considered significant. 
Pearson correlation coefficient (r value) was used for the relationship 
between continuous variables, including AUC of heteroresistance and 
efflux of R6G, MIC, fungal burden in CSF, Glasgow Coma Score, and 
CSF opening pressure. The Kruskal-Wallis test was used for chromo-
somal disomy (categorical variable) and efflux (continuous variable).
Study approval. Studies in humans were reviewed and approved 
by the Observational/Interventions Research Ethics Committee, Lon-
don School of Hygiene and Tropical Medicine, London, United King-
dom, and the Medical Research Coordinating Committee, National 
Institute of Medical Research, Dar es Salaam, United Republic of 
Tanzania. All study conduct was performed in line with Good Clinical 
Practice guidelines and the World Medical Association’s Declaration 
of Helsinki. Study subjects provided informed consent prior to their 
participation in the study. If study subjects were unable to provide 
informed consent due to their medical condition, informed consent 
was obtained on their behalf from their next of kin.
Author contributions
NRHS, WH, and TB conceived the research question and clinical 
study with input from JKC. NRHS, SK, SFM, SM, and J Rugemalila 
conducted the clinical study, recruited patients, and collected clin-
ical samples. TSH was the Principal Investigator of the ACTA tri-
al, within which this study was embedded. NRHS conducted the 
onsite laboratory experiments and DNA extraction. NRHS and JB 
conceived the in vitro experiments. NRHS, ESS, and LN performed 
rpm. Every 24 hours, 1 ml was removed from each tube for quantita-
tive cryptococcal cultures on both plain YPD and YPD with FLC added 
(as described earlier).
R6G efflux assay. Dynamics of R6G efflux were used to investi-
gate ATP binding cassette (ABC) type drug transporter activity. After 
overnight growth to log phase in liquid YPD at 37°C, 109 cells were 
inoculated into 20 ml fresh YPD and incubated at 30°C for 2 hours. 
Following centrifugation, the cell pellet was washed twice in PBS. 
Cells were resuspended in 10 ml of PBS. A quantity of 20 μM R6G 
(Sigma-Aldrich) was then added and the cells were vortexed before 
incubation at 30°C for 2 hours to allow cellular uptake of the dye. The 
cell pellet was then washed twice in PBS and resuspended in 5 ml fresh 
PBS. A quantity of 750 μl of this suspension was then aliquoted into 
microcentrifuge tubes, and 250 μl of either PBS or PBS with 8 mM glu-
cose was added to each tube to make a final volume of 1 ml. Tubes 
were incubated at 35°C. After 30 minutes and then 1 hour incubation 
timepoints, tubes were removed and centrifuged at 805 g for 2 min-
utes. A quantity of 200 μl supernatant was transferred to a shallow 
96-well plate and placed in an automatic plate reader (Synergy HT, 
BioTek). Fluorescence was measured at an excitation wavelength of 
527 nm and an emission wavelength of 555 nm. Efflux in glucose-free 
supernatants was subtracted from that in glucose-containing superna-
tants to give an efflux value in relative fluorescence units (RFUs). C. 
neoformans H99 efflux was tested in each experiment, allowing efflux 
of each strain to be normalized to that of H99 and expressed as a ratio.
RT-PCR. Expression of the AFR1 and ERG11 genes was quantified by 
real-time reverse transcription PCR (RT-PCR). Yeast cells from strains 
H99, 0101, and 1601 were grown to logarithmic phase in YPD medium 
at 30°C with shaking. Each culture was then supplemented with 64 μg/
ml FLC and allowed to incubate for 1 hour at 30°C with shaking. Cells 
were harvested by centrifugation, washed, and mechanically disrupt-
ed by vortexing (TissueLyser, Qiagen) with beads. Total RNA was then 
purified with the Qiagen RNeasy Mini Kit, including treatment with 
RNase-free DNase. cDNA was synthesized using the iScript Reverse 
Transcription Supermix (Bio-Rad). RT-PCR reactions were performed 
in triplicate using iTaq SYBR Green Supermix with the CFX96 Real-
Time PCR Detection System (Bio-Rad). Data were normalized to the 
expression of glyceraldehyde-3-phosphate dehydrogenase (GPD). The 
AFR1 primers used for RT-PCR were forward 5′-CCCACTTTGCCAT-
ACTTTTGG-3’, and reverse 5′-AACTGTGGAGACAAGACCACTGA-
TAA-3′. The Erg11 primers used were forward 5′-TGGCAAGACGC-
CAAAGTCT-3′, reverse 5′-GGCGGCAAATCCCTTTTC-3′.
DNA extraction and sequencing. Individual colonies (grown on YPD 
or YPD plus FLC) after a single passage from patient CSF were stored 
on Microbank beads (Pro-Lab Diagnostics) at –80°C. DNA extraction 
was performed on individual colonies after a single passage of the 
Microbank beads in pure culture onto YPD agar. Extraction method 
was with modification of the protocol for use of the Masterpure Yeast 
DNA Purification Kit (Epicentre), including a bead-beating step to dis-
rupt the cryptococcal capsule (35). The bead beater (Tissuelyser LT, 
Qiagen) was used at 2 cycles of 1 minute each at 1/50 second. Quan-
tification of DNA was performed by Qubit (Thermo Fisher Scientific). 
Shearing was performed using Covaris S220 (Covaris). The settings 
used were a 5% duty cycle, 200 cycles per burst, for 55 seconds, with 
the water bath cooled to below 8°C. For 100 ng gDNA in 54 μl volume 
in an Adaptive Focused Acoustics snap tube (Covaris), this gave a size 
profile with a median fragment size of approximately 400–450 bp. 
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